Szilard Voros, MD, discusses what he found the most interesting at the 2013 ADA and singles out the new SGLT2 inhibitor class of drugs as especially exciting. However, he cautions that they are very new and only time will tell regarding any safety aspects. He is intrigued by the concept and the weight loss component is also a very positive aspect.
Other videos with Dr. Voros:
- Szilard Voros, MD, FACC, FSCCT, FAHA: Introduction
- New Panel of Tests (DPMP) Identifies Diabetes and CV Risk Earlier
- Beta-cell Dysfunction Not Always Seen with Standard Tests
- What A1c Level Indicates Prediabetes?
- What are the Bio-markers of Beta-cell Dysfunction?
- Testing for Type 1, 1.5, 2 Diabetes
- Is Health Diagnostic Laboratory’s New Test Panel for Diabetes Available?
- Could the Health Diagnostics Lab test replace other older tests?
- How Is the DPMP Test Done?
- With the DPMP, are providers given analysis with suggested actions?
- Does the DPMP include CV data?
- Are insurance companies paying for DPMP test yet?
- Is Cycloset under-appreciated for CV benefits?
- Improved patient outcomes with DPMP test results
Szilard Voros, MD, FACC, FSCCT, FAHA, is a Hungarian-born American cardiologist and globally renowned leading research scientist in advanced cardiovascular imaging, biomarkers, lipoprotein metabolism and genomics. He currently serves as an Associate Professor of Medicine/Cardiology and Radiology, and Director of Advanced Cardiovascular MR and CT Research at the Department of Radiology and Cardiology at Stony Brook University Medical Center, State University of New York. He previously served as the Chief Scientific Officer, Chief of Cardiovascular Prevention, and Medical Director of Cardiac MR and CT at Piedmont Hospital in Atlanta, Georgia, and as a Clinical Associate Professor of Medicine at the Medical College of Georgia. He is a founding member and Fellow of the Society of Cardiovascular Computed Tomography (FSCCT), Fellow of the American College of Cardiology (FACC) and Fellow of the American Heart Association (FAHA).